Class Action Lawsuit Filed Against Gossamer Bio, Inc. Over Failed Clinical Trial Results
A class action lawsuit has been filed against Gossamer Bio, Inc. (NASDAQ: GOSS) following the failure of its Phase 3 PROSERA study, which did not meet its primary endpoint. The lawsuit alleges securities fraud or other unlawful business practices. The company's stock price dropped significantly after the announcement of the failed trial results.
Tickers: $GOSS
Topics: class action lawsuit Gossamer Bio Phase 3 trial failure securities fraud stock price drop